A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter,Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort toEvaluate the Safety, Tolerability, and Efficacy of MK-8457 + MTX in Patients withActive Rheumatoid Arthritis Despite Methotrexate Therapy - Proof-of-Concept of MK-8457 in patients with Rheumatoid Arthritis

Merck, Sharpe & Dohme Corp., a subsidiary of Merck & Co. Inc (hereafter referred to as Merck)0 sites342 target enrollmentApril 16, 2012

Conditionsactive rheumatoid arthritis Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: active rheumatoid arthritis
Sponsor: Merck, Sharpe & Dohme Corp., a subsidiary of Merck & Co. Inc (hereafter referred to as Merck)
Enrollment: 342
Status: Active, not recruiting
Last Updated: 12 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

April 16, 2012

End Date

TBD

Last Updated

12 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

Merck, Sharpe & Dohme Corp., a subsidiary of Merck & Co. Inc (hereafter referred to as Merck)

Eligibility Criteria

Inclusion Criteria

•Subject must be \=18 years of age on the day of signing the informed consent.
•RA diagnosis and disease activity:
•Subject has a diagnosis of RA for at least 6 months prior to screening.
•Subject has active RA as defined by the presence of 6 swollen joints (of 66 joint count) AND 6 tender joints (of 68 joint count) at screening (Visit 1\) and baseline (Visit 2\).
•Subject has a C\-reactive protein (CRP) blood level \> 0\.9 mg/dL from the central reference laboratory at screening.
•Subject is anti\-cyclic citrullinated antibody positive and/or rheumatoid factor positive at screening.
•Subject is ACR functional Class I, II, or III.
•Subjects has received MTX for a minimum of 3 months with a regionally appropriate stable weekly dose (15\-25 mg/wk for regions outside of Asia, 6–25 mg/week for Asia) for at least 4 wks prior to entering study.
•Subject must meet all Tuberculosis (TB) screening criteria: No history of untreated latent or active TB prior to baseline; Has no signs or symptoms suggestive of active TB; Has had no recent close contact with a person with active TB (if there has been contact, patient will be evaluated and receive appropriate treatment for latent TB at least 4 weeks prior to first dose of study medication; Within 4 weeks prior to first administration of study medication, has negative diagnostic TB test result ; has a chest radiograph within two months prior to screening with no evidence of current or old inactive TB
•Are the trial subjects under 18? no

Exclusion Criteria

•Subject has inflammatory disease other than RA, including but not limited to psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, or Lyme disease.
•Previous exposure to fostamatinib or other splenic tyrosine kinase (SYK) inhibitors.
•Previous exposure to TNF\-alpha targeted therapy or any biological agents for RA.
•Subject has received any treatment listed below more recently than the indicated washout period prior to Screening.
•Prohibited Medications, Supplements, and Other SubstancesWashout Period Prior to Screening
•Disease modifying anti\-rheumatic drugs such as but not limited to (not including cytotoxic agents):
•Leflunomide, cyclosporine, mycophenolate mofetil, azathioprine, corticosteroids (parenteral, intra\-articular), sulfasalazine, hydroxychloroquine30 days (8 weeks for leflunomide unless subject undergoes standard cholestyramine or activated charcoal washout)
•Cytotoxic agents including chlorambucil, cyclophosphamide, nitrogen mustard, or other alkylating agents3 months
•Live vaccinations1 month
•Investigational medications30 days or 5 half lives of the investigational agent whichever is longer